Assessing Attitudes and Experiences of Early Adopters of Personalized Genomics

评估个性化基因组学早期采用者的态度和经验

• 批准号: 7936359
• 负责人: Barbara A. Bernhardt
• 金额: $ 33.73万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-22 至 2012-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7936359
• 关键词: Access to Information; Accounting; Address; Area; Attention; Attitude; Behavior; Behavioral; Benefits and Risks; Bioethics; Caring; Clinical; Collaborations; Complex; Coronary Arteriosclerosis; Data; Diabetes Mellitus; Disease; Disease Outcome; Educational Materials; Ensure; Ethics; Genes; Genetic; Genetic Variation; Genomics; Health; Healthcare; Human; Human Genetics; Human Genome; Individual; Informed Consent; Institutes; Interview; Knowledge; Lead; Malignant Neoplasms; Measures; Medicine; Methodology; Motivation; New Jersey; Outcome; Participant; Pennsylvania; Perception; Persons; Pharmaceutical Preparations; Policies; Qualitative Methods; Recommendation; Research; Research Personnel; Risk; Risk Assessment; Sampling; Surveys; Technology; Testing; Universities; Variant; Work; base; disorder risk; early experience; ethical legal social implication; expectation; experience; genome wide association study; improved; interest; knowledge base; member; research clinical testing; response; social; trait

DESCRIPTION (provided by applicant): This application addresses broad Challenge Area (02) Bioethics and specific Challenge Topic, 02-HG-102 Direct to Consumer (DTC) Personal Genomics-Ethical, Legal and Social Implications Research. Completing the Human Genome and the Human HapMap Projects has enabled studies associating genetic variation with complex diseases such as various cancers, coronary artery disease, and diabetes. This has led to the emergence of direct-to-consumer testing companies offering genomic profiling to inform individuals about their risk for dozens of diseases and traits. Such testing is being offered with the assumption that identification of an increased risk could lead to preventative measures to reduce a person's risk for developing disease or to improve disease outcome. Although personalized medicine is gaining clinical and policy attention and appears to be technically feasible, little is known about the public's understanding and perceptions of such care, nor about their assessment of its risks and benefits. We are proposing a project that capitalizes on the expertise of researchers at the University of Pennsylvania to investigate public response to personalized medicine. The proposed study will take advantage of the Coriell Personalized Medicine Collaborative (CPMC) conducted at the Coriell Institute in Camden, NJ. The CPMC aims to determine the clinical utility of personalized medicine by offering participants a personalized genomic risk assessment for a variety of diseases and collecting data on health outcomes. While not a direct-to-consumer company the CPMC study offers a unique opportunity to assess the social, behavioral, and ethical implications of direct availability of personalized genomic risk assessment. The specific aims of our project are to: 1) Assess motivations and perceived utility of personalized genomic risk assessment among individuals who express interest in the CPMC; 2) Explore participant understanding of their results, the use of the information, and educational needs; and 3) Develop policy recommendations for the ethical offering of personalized genomic disease risk assessment. We will use a mixed methodology for addressing these study aims. For specific aim 1, we will survey approximately 1000 individuals who register for a CPMC informed consent session, regardless of whether they actually attend or provide a sample for testing. For specific aim 2, we will interview 60 CPMC participants 3-6 months after they receive their results. For specific aim 3, we will work with members of the research-to-policy core of the Penn Center for the Integration of Genetic Healthcare Technologies (Penn CIGHT) to develop and disseminate policy recommendations for the responsible and ethical offering of genomic tests that takes into account the misperceptions, concerns, and educational needs of consumers. As direct-to-consumer genomic testing becomes more common, policies and educational materials are needed to ensure that health care consumers derive maximal benefit from this type of testing. This project will identify misperceptions, concerns and educational needs of a diverse group of health care consumers who are offered the opportunity to have genomic risk assessment. Findings from this study will be the basis of policy recommendations for the ethical offering of genomic testing directly to the consumer.

描述（由申请人提供）：本申请涉及广泛的挑战领域（02）生物伦理学和特定的挑战主题，02-HG-102直接面向消费者（DTC）个人基因组学-伦理，法律的和社会影响研究。人类基因组和人类单体型图项目的完成使研究能够将遗传变异与各种癌症、冠状动脉疾病和糖尿病等复杂疾病联系起来。这导致了直接面向消费者的检测公司的出现，这些公司提供基因组分析，以告知个人他们患数十种疾病和特征的风险。提供这种检测的假设是，确定增加的风险可能导致预防措施，以减少一个人患疾病的风险或改善疾病的结果。虽然个性化医疗正在获得临床和政策的关注，似乎在技术上是可行的，但人们对公众对这种护理的理解和看法知之甚少，也不知道他们对这种护理的风险和益处的评估。我们正在提出一个项目，利用宾夕法尼亚大学研究人员的专业知识，调查公众对个性化医疗的反应。拟议的研究将利用新泽西州卡姆登Coriell研究所进行的Coriell个性化医学合作（CPMC）。CPMC旨在通过为参与者提供各种疾病的个性化基因组风险评估并收集有关健康结果的数据来确定个性化医疗的临床效用。虽然不是一家直接面向消费者的公司，但CPMC的研究提供了一个独特的机会来评估直接提供个性化基因组风险评估的社会，行为和伦理影响。我们项目的具体目标是：1）评估对CPMC感兴趣的个人中个性化基因组风险评估的动机和感知效用; 2）探索参与者对其结果的理解，信息的使用和教育需求; 3）制定个性化基因组疾病风险评估的道德提供政策建议。我们将使用混合的方法来解决这些研究目标。对于具体目标1，我们将调查约1000名注册参加CPMC知情同意会议的个人，无论他们是否实际参加或提供样本进行检测。对于具体目标2，我们将在60名CPMC参与者收到结果后3-6个月进行访谈。对于具体目标3，我们将与宾夕法尼亚州遗传医疗技术整合中心（Penn CIGHT）的研究到政策核心成员合作，制定和传播关于负责任和道德的基因组检测的政策建议，考虑到消费者的误解，担忧和教育需求。随着直接面向消费者的基因组检测变得越来越普遍，需要制定政策和教育材料，以确保医疗保健消费者从此类检测中获得最大利益。该项目将确定不同群体的医疗保健消费者的误解，关注和教育需求，他们有机会进行基因组风险评估。这项研究的结果将成为直接向消费者提供合乎道德的基因组检测的政策建议的基础。